CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will participate in the Cowen 44th Annual Health Care Conference, which is taking place at the Marriott Copley Place in Boston from March 4-6, 2024, to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Chief Executive Officer, Brett Hall, Chief Scientific Officer, Harold “E.B.” Brakewood, Chief Business Officer, and Mallory Morales, Chief Accounting Officer, Treasurer.
Format: Panel Discussion and 1x1 Investor Meetings
Panel Discussion: Titled ‘Targeted Oncology’ on March 5 from 12:50 to 1:50 PM ET
The presentations will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.
About Immuneering Corporation
Immuneering is a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy. The Company aims to achieve universal activity through deep cyclic inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneering’s lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor currently in a Phase 1/2a study in patients with advanced solid tumors harboring RAS mutations. IMM-6-415 is an oral, twice-daily deep cyclic inhibitor and will be evaluated in a Phase 1/2a study in patients with advanced solid tumors harboring RAS or RAF mutations. The company’s development pipeline also includes several early-stage programs. For more information, please visit www.immuneering.com.
Media Contact:
Gina Nugent
Nugent Communications
617-460-3579
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contacts:
Laurence Watts
Gilmartin Group
619-916-7620
This email address is being protected from spambots. You need JavaScript enabled to view it.
or
Kiki Patel, PharmD
Gilmartin Group
332-895-3225
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.25 |
| Daily Change: | -0.08 -3.43 |
| Daily Volume: | 359,797 |
| Market Cap: | US$69.860M |
December 19, 2024 November 13, 2024 October 15, 2024 | |
Surf Air Mobility is a regional air mobility platform expanding the category of regional air travel to reinvent flying through the power of electrification. In an effort to substantially reduce the cost and environmental impact of...
CLICK TO LEARN MORE
Leveraging its vertically-integrated approach from mine to material manufacturing, Graphite One intends to produce high-grade anode material for the lithium-ion electric vehicle battery market and energy storage systems...
CLICK TO LEARN MORE
